CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc.
07.07.2025
Swiss Innovators celebrated worldwide (startupticker.ch)
05.03.2024
Business wind down and take off for listed Swiss startups (startupticker.ch)
17.11.2023
Green light for world’s first CRISPR gene-edited therapy (startupticker.ch)
28.03.2023
CRISPR Therapeutics inks licensing deal worth up to USD 330 million (venturelab.swiss)
28.03.2023
Up to $230 million for CRISPR Therapeutics (startupticker.ch)
No milestones
No Jobs
No videos and documents
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Being among the TOP 100 Startups in Switzerland has become a seal of approval for founders, and the TOP 100 Swiss Startup Ranking provides them with the recognition they deserve. As startups cannot appear in the startup ranking for more than five years after incorporation, the TOP 100 Swiss Scale-up Ranking has been introduced. A growth jury is asked to select the TOP 100 Swiss Scale-ups. These companies, aged five up to 10 years, show the greatest potential for further growth and represent the future Swiss unicorns
Website:
crisprtx.com
Headquarter:
Zug
Foundation Date:
October 2013
Technology:
Sectors: